49662 Federal Register / Vol. 82, No. 206 / Thursday, October 26, 2017 / Notices 

rules, and posthearing briefs, which 

must conform with the provisions of 

section 207.67 of the Commission’s 

rules. The deadline for filing 

posthearing briefs is March 9, 2018. In 

addition, any person who has not 

entered an appearance as a party to the 

review may submit a written statement 

of information pertinent to the subject of 

the review on or before March 9, 2018. 

On April 3, 2018, the Commission will 

make available to parties all information 

on which they have not had an 

opportunity to comment. Parties may 

submit final comments on this 

information on or before April 5, 2018, 

but such final comments must not 

contain new factual information and 

must otherwise comply with section 

207.68 of the Commission’s rules. All 

written submissions must conform with 

the provisions of section 201.8 of the 

Commission’s rules; any submissions 

that contain BPI must also conform with 

the requirements of sections 201.6, 

207.3, and 207.7 of the Commission’s 

rules. The Commission’s Handbook on 

E-Filing, available on the Commission’s 

Web site at https://edis.usitc.gov, 

elaborates upon the Commission’s rules 

with respect to electronic filing. 

Additional written submissions to the 

Commission, including requests 

pursuant to section 201.12 of the 

Commission’s rules, shall not be 

accepted unless good cause is shown for 

accepting such submissions, or unless 

the submission is pursuant to a specific 

request by a Commissioner or 

Commission staff. 

In accordance with sections 201.16(c) 

and 207.3 of the Commission’s rules, 

each document filed by a party to the 

review must be served on all other 

parties to the review (as identified by 

either the public or BPI service list), and 

a certificate of service must be timely 

filed. The Secretary will not accept a 

document for filing without a certificate 

of service. 

Authority: This review is being 

conducted under authority of title VII of 

the Tariff Act of 1930; this notice is 

published pursuant to section 207.62 of 

the Commission’s rules. 

By order of the Commission. 

Issued: October 23, 2017. 

Lisa R. Barton, 

Secretary to the Commission. 

[FR Doc. 2017–23314 Filed 10–25–17; 8:45 am] 

BILLING CODE 7020–02–P 

INTERNATIONAL TRADE 

COMMISSION 

Notice of Receipt of Complaint; 

Solicitation of Comments Relating to 

the Public Interest 

AGENCY: U.S. International Trade 

Commission. 

ACTION: Notice. 

SUMMARY: Notice is hereby given that 

the U.S. International Trade 

Commission has received a complaint 

entitled Certain Glucosylated Steviol 

Glycosides, and Products Containing 

Same, DN 3266; the Commission is 

soliciting comments on any public 

interest issues raised by the complaint 

or complainant’s filing pursuant to the 

Commission’s Rules of Practice and 

Procedure. 

FOR FURTHER INFORMATION CONTACT: Lisa 

R. Barton, Secretary to the Commission, 

U.S. International Trade Commission, 

500 E Street SW., Washington, DC 

20436, telephone (202) 205–2000. The 

public version of the complaint can be 

accessed on the Commission’s 

Electronic Document Information 

System (EDIS) at https://edis.usitc.gov, 

and will be available for inspection 

during official business hours (8:45 a.m. 

to 5:15 p.m.) in the Office of the 

Secretary, U.S. International Trade 

Commission, 500 E Street SW., 

Washington, DC 20436, telephone (202) 

205–2000. 

General information concerning the 

Commission may also be obtained by 

accessing its Internet server at United 

States International Trade Commission 

(USITC) at https://www.usitc.gov. The 

public record for this investigation may 

be viewed on the Commission’s 

Electronic Document Information 

System (EDIS) at https://edis.usitc.gov. 

Hearing-impaired persons are advised 

that information on this matter can be 

obtained by contacting the 

Commission’s TDD terminal on (202) 

205–1810. 

SUPPLEMENTARY INFORMATION: The 

Commission has received a complaint 

and a submission pursuant to § 210.8(b) 

of the Commission’s Rules of Practice 

and Procedure filed on behalf of 

PureCircle USA Inc. and PureCircle Sdn 

Bhd on October 20, 2017. The complaint 

alleges violations of section 337 of the 

Tariff Act of 1930 (19 U.S.C. 1337) in 

the importation into the United States, 

the sale for importation, and the sale 

within the United States after 

importation of certain glucosylated 

steviol glycosides, and products 

containing same. The complaint names 

as respondents Sweet Green Fields USA 

LLC of Bellingham, WA; Sweet Green 

Fields Co., Ltd of Bellingham, WA; and 

Ningbo Green-Health Pharma-ceutical 

Co., Ltd. a/k/a NB Green-Health 

Pharma-ceutical Co., Ltd. of China. The 

complainant requests that the 

Commission issue a limited exclusion 

order, cease and desist orders, and 

impose a bond upon respondents’ 

alleged infringing articles during the 60- 

day Presidential review period pursuant 

to 19 U.S.C. 1337(j). 

Proposed respondents, other 

interested parties, and members of the 

public are invited to file comments, not 

to exceed five (5) pages in length, 

inclusive of attachments, on any public 

interest issues raised by the complaint 

or § 210.8(b) filing. Comments should 

address whether issuance of the relief 

specifically requested by the 

complainant in this investigation would 

affect the public health and welfare in 

the United States, competitive 

conditions in the United States 

economy, the production of like or 

directly competitive articles in the 

United States, or United States 

consumers. 

In particular, the Commission is 

interested in comments that: 

(i) Explain how the articles 

potentially subject to the requested 

remedial orders are used in the United 

States; 

(ii) identify any public health, safety, 

or welfare concerns in the United States 

relating to the requested remedial 

orders; 

(iii) identify like or directly 

competitive articles that complainant, 

its licensees, or third parties make in the 

United States which could replace the 

subject articles if they were to be 

excluded; 

(iv) indicate whether complainant, 

complainant’s licensees, and/or third 

party suppliers have the capacity to 

replace the volume of articles 

potentially subject to the requested 

exclusion order and/or a cease and 

desist order within a commercially 

reasonable time; and 

(v) explain how the requested 

remedial orders would impact United 

States consumers. 

Written submissions must be filed no 

later than by close of business, eight 

calendar days after the date of 

publication of this notice in the Federal 

Register. There will be further 

opportunities for comment on the 

public interest after the issuance of any 

final initial determination in this 

investigation. 

Persons filing written submissions 

must file the original document 

electronically on or before the deadlines 

stated above and submit 8 true paper 

copies to the Office of the Secretary by 


ethrower on DSK3G9T082PROD with NOTICES
Federal Register / Vol. 82, No. 206 / Thursday, October 26, 2017 / Notices 49663 

1Handbook for Electronic Filing Procedures: 

https://www.usitc.gov/documents/handbook_on_

filing_procedures.pdf. 

2All contract personnel will sign appropriate 

nondisclosure agreements. 

3Electronic Document Information System 

(EDIS): https://edis.usitc.gov. 

noon the next day pursuant to § 210.4(f) 

of the Commission’s Rules of Practice 

and Procedure (19 CFR 210.4(f)). 

Submissions should refer to the docket 

number (‘‘Docket No. 3266’’) in a 

prominent place on the cover page and/ 

or the first page. (See Handbook for 

Electronic Filing Procedures, Electronic 

Filing Procedures 1). Persons with 

questions regarding filing should 

contact the Secretary (202–205–2000). 

Any person desiring to submit a 

document to the Commission in 

confidence must request confidential 

treatment. All such requests should be 

directed to the Secretary to the 

Commission and must include a full 

statement of the reasons why the 

Commission should grant such 

treatment. See 19 CFR 201.6. Documents 

for which confidential treatment by the 

Commission is properly sought will be 

treated accordingly. All such requests 

should be directed to the Secretary to 

the Commission and must include a full 

statement of the reasons why the 

Commission should grant such 

treatment. See 19 CFR 201.6. Documents 

for which confidential treatment by the 

Commission is properly sought will be 

treated accordingly. All information, 

including confidential business 

information and documents for which 

confidential treatment is properly 

sought, submitted to the Commission for 

purposes of this Investigation may be 

disclosed to and used: (i) By the 

Commission, its employees and Offices, 

and contract personnel (a) for 

developing or maintaining the records 

of this or a related proceeding, or (b) in 

internal investigations, audits, reviews, 

and evaluations relating to the 

programs, personnel, and operations of 

the Commission including under 5 

U.S.C. Appendix 3; or (ii) by U.S. 

government employees and contract 

personnel,2 solely for cybersecurity 

purposes. All nonconfidential written 

submissions will be available for public 

inspection at the Office of the Secretary 

and on EDIS.3

This action is taken under the 

authority of section 337 of the Tariff Act 

of 1930, as amended (19 U.S.C. 1337), 

and of §§ 201.10 and 210.8(c) of the 

Commission’s Rules of Practice and 

Procedure (19 CFR 201.10, 210.8(c)). 

By order of the Commission. 

Issued: October 20, 2017. 

Lisa R. Barton, 

Secretary to the Commission. 

[FR Doc. 2017–23233 Filed 10–25–17; 8:45 am] 

BILLING CODE 7020–02–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–392] 

Importer of Controlled Substances 

Application: Galephar Pharmaceutical 

Research, Inc. 

ACTION: Notice of application. 

DATES: Registered bulk manufacturers of 

the affected basic classes, and 

applicants therefore, may file written 

comments on or objections to the 

issuance of the proposed registration on 

or before November 27, 2017. Such 

persons may also file a written request 

for a hearing on the application on or 

before November 27, 2017. 

ADDRESSES: Written comments should 

be sent to: Drug Enforcement 

Administration, Attention: DEA Federal 

Register Representative/DRW, 8701 

Morrissette Drive, Springfield, Virginia 

22152. All requests for hearing must be 

sent to: Drug Enforcement 

Administration, Attn: Administrator, 

8701 Morrissette Drive, Springfield, 

Virginia 22152. All requests for hearing 

should also be sent to: (1) Drug 

Enforcement Administration, Attn: 

Hearing Clerk/LJ, 8701 Morrissette 

Drive, Springfield, Virginia 22152; and 

(2) Drug Enforcement Administration, 

Attn: DEA Federal Register 

Representative/DRW, 8701 Morrissette 

Drive, Springfield, Virginia 22152. 

SUPPLEMENTARY INFORMATION: The 

Attorney General has delegated his 

authority under the Controlled 

Substances Act to the Administrator of 

the Drug Enforcement Administration 

(DEA), 28 CFR 0.100(b). Authority to 

exercise all necessary functions with 

respect to the promulgation and 

implementation of 21 CFR part 1301, 

incident to the registration of 

manufacturers, distributors, dispensers, 

importers, and exporters of controlled 

substances (other than final orders in 

connection with suspension, denial, or 

revocation of registration) has been 

redelegated to the Assistant 

Administrator of the DEA Diversion 

Control Division (‘‘Assistant 

Administrator’’) pursuant to section 7 of 

28 CFR part 0, appendix to subpart R. 

In accordance with 21 CFR 

1301.34(a), this is notice that on August 

2, 2017, Galephar Pharmaceutical 

Research, Inc., #100 Carr 198, Industrial 

Park, Juncos, Puerto Rico 00777–3873 

applied to be registered as an importer 

of hydromorphone (9150), a basic class 

of controlled substance in schedule II. 

The company plans to import the 

listed controlled substance in finished 

dosage form for clinical trials, research 

and analytical purposes. 

The import of this class of controlled 

substance will be granted only for 

analytical testing, research, and clinical 

trials. This authorization does not 

extend to the import of a finished FDA 

approved or non-approved dosage form 

for commercial sale. 

Dated: October 18, 2017. 

Demetra Ashley, 

Acting Assistant Administrator. 

[FR Doc. 2017–23328 Filed 10–25–17; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. 17–28] 

Yoon H. Choi, M.D.; Decision and 

Order 

On April 4, 2017, the Assistant 

Administrator, Division of Diversion 

Control, issued an Order to Show Cause 

to Yoon H. Choi, M.D. (Respondent), of 

Brockton, Massachusetts. The Show 

Cause Order proposed the revocation of 

Respondent’s DEA Certificate of 

Registration as a practitioner, on the 

ground that he does not have authority 

to dispense controlled substances in 

Massachusetts, the State in which he is 

registered with the Agency. Show Cause 

Order, at 1. 

As to the Agency’s jurisdiction, the 

Show Cause Order alleged that 

Respondent holds DEA Certificate of 

Registration No. BC6966381, which 

authorizes him to dispense controlled 

substances in schedules II through V as 

a practitioner, at the registered address 

of Steward Medical Group, One Pearl 

Street, Suite 2200, Brockton, 

Massachusetts. Id. The Show Cause 

Order alleged that this registration does 

not expire until August 31, 2018. Id. 

As to the substantive ground for the 

proceeding, the Show Cause Order 

alleged that ‘‘[o]n January 5, 2017, the 

Commonwealth of Massachusetts Board 

of Registration in Medicine indefinitely 

suspended [his] medical license’’ and 

that ‘‘[t]his order remains in effect.’’ Id. 

The Order thus alleged that Respondent 

is ‘‘without authority to handle 

controlled substances in . . . 

Massachusetts, the [S]tate in which [he 

is] registered,’’ that he is ‘‘required to 


ethrower on DSK3G9T082PROD with NOTICES